Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Albemarle Corporation (NYSE: ALB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Virginia-incorporated public company with common stock listed on the NYSE, Albemarle regularly submits reports that cover financial results, material agreements, governance updates and other significant events.
Among the key documents are Form 8-K current reports, where Albemarle discloses items such as quarterly earnings releases, material definitive agreements, goodwill impairment conclusions, director and officer changes, and organizational structure updates. For example, recent 8-K filings have described the company’s third quarter results, the stock purchase agreement related to the sale of a controlling stake in Ketjen’s refining catalyst solutions business, the planned sale of its interest in the Eurecat joint venture, and changes in senior leadership roles.
Investors can also use this page to locate references to Albemarle’s use of proceeds from portfolio transactions, its assessment of impairment charges, and its classification of certain businesses as held for sale. These filings help explain how Albemarle manages its lithium, bromine and catalyst-related operations within its broader financial and strategic framework.
Stock Titan enhances access to Albemarle’s filings by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy documents. Users can quickly understand the implications of new 8-Ks, as well as the content of other core filings such as annual and quarterly reports, and can review disclosures related to executive arrangements and board changes without reading every line of the original text.
Albemarle Corporation reported a Form 144 notice to sell 11,783 shares. The filing lists Goldman Sachs & Co. LLC as the broker and an aggregate amount of $1,962,340.82. The securities were acquired as compensation (Restricted Stock Units) on 02/26/2026, 02/18/2022, and 05/05/2023, with per‑lot quantities of 5,108, 3,568, and 3,107 shares respectively.
Albemarle Corporation has completed the sale of its 51% ownership interest in Ketjen Corporation to an affiliate of KPS Capital Partners, while retaining a 49% minority stake. Albemarle expects approximately $547 million in cash from the Ketjen sale, including $22 million of cash held by Ketjen.
Combined with the earlier sale of its 50% interest in the Eurecat joint venture to Axens SA, Albemarle’s pre-tax proceeds from the two transactions total about $670 million. The company plans to use these funds for debt reduction, including cash tender offers of up to $500 million for several series of senior notes and the full redemption of $650,000,000 of 4.650% Senior Notes due 2027.
Sheorey Neal Ravi reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corporation’s Chief Financial Officer, Neal Ravi Sheorey, received an equity award of 4,490 shares in the form of restricted stock units at a grant price of $0 per share. These units vest 100% on 03/02/2029, subject to the terms of the applicable award agreement.
The filing also updates his reported holdings to a total of 20,931 shares after the transaction. This amount now includes 4,231 unvested restricted stock units that vest 100% on 02/22/2027, which are being reported as beneficially owned common stock to align reporting methodology among Albemarle insiders.
Norris Eric reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corporation reported that Chief Commercial Officer Eric Norris received a grant of 4,490 restricted stock units on March 2, 2026. The award has no purchase price and will vest 100% on March 2, 2029, subject to the terms of the award agreement. Following this grant, Norris beneficially owns 53,443 shares of Albemarle common stock directly.
LaBauve Donald J. Jr. reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corporation executive Donald J. LaBauve Jr., VP, Corporate Controller & CAO, received an award of 698 shares of Common Stock on a grant/award basis at $0.00 per share. Following this award, his directly held Common Stock totaled 10,402 shares.
A related footnote explains that these are restricted stock units that vest 100% on March 2, 2029, subject to the award agreement. He also reported 12,755 shares of Common Stock held indirectly through the Albemarle Corporation Retirement Savings Plan.
Krupa Ander C. reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corp reported that its General Counsel & Secretary, Ander C. Krupa, was granted 1,796 restricted stock units on March 2, 2026. According to the award terms, these restricted stock units vest 100% on March 2, 2029, increasing the officer’s directly held common stock-related interest to 13,184 shares after the award.
Mummert Mark Richard reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corp’s Chief Supply Chain Officer, Mark Richard Mummert, received an equity award of 3,143 shares of common stock on 03/02/2026. The award is in the form of Restricted Stock Units that vest 100% on 03/02/2029, subject to the terms of the award agreement. Following this grant, his directly owned common stock holdings total 17,515 shares.
Albemarle Corporation’s Chairman and CEO J Kent Masters reported an equity award. He acquired 22,450 shares in the form of restricted stock units granted at no cash cost, which vest 100% on 03/30/2027. Following this grant, he beneficially owns 146,411 common shares directly.
Anderson Melissa H. reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corporation executive Melissa H. Anderson, Chief Business Transformation Officer, received a grant of 4,490 shares of common stock on March 2, 2026, at no cost as a stock award. These restricted stock units vest 100% on June 30, 2027, under the award agreement. Following the grant, she directly holds 14,002 shares of common stock and indirectly holds 179.1617 shares through the Albemarle Savings Plan.
Gagarinas Autumn M. reported acquisition or exercise transactions in this Form 4 filing.
Albemarle Corp’s Chief People Officer, Autumn M. Gagarinas, reported an equity award on a Form 4. She received 1,796 shares of common stock in the form of Restricted Stock Units at a stated price of $0.00 per share, bringing her direct holdings to 5,393 shares. The RSUs vest 100% on 03/02/2029, subject to the terms of the award agreement.